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A B S T R A C T
Purpose: Lacosamide (LCM) and carbamazepine (CBZ) are antiepileptic drugs both acting on neuronal
voltage-gated sodium channels. Patch-clamp studies demonstrated signiﬁcant differences in how LCM
and CBZ affect neuronal membrane excitability. Despite valuable information patch-clamp studies
provide, they also comprise some constraints. For example, little is known about effects of LCM on
intracortical synaptic excitability. In contrast, transcranial magnetic stimulation (TMS) can describe
drug-induced changes at the system level of the human cerebral cortex.
Methods: The present study was designed to explore dose-depended effects of LCM and effects of CBZ on
motor cortex excitability with TMS in a randomized, double-blind, placebo-controlled crossover trial in
healthy human subjects. Subjects received 600 mg CBZ, 200 mg LCM, 400 mg LCM or placebo preceding
TMS measurements.
Results: Compared to placebo, TMS motor thresholds were signiﬁcantly increased after carbamazepine
and lacosamide, with a trend for a dose dependent effect of lacosamide. Both, carbamazepine and
lacosamide did not affect TMS parameters of intracortical synaptic excitability.
Conclusions: TMS measurements suggest that lacosamide and carbamazepine predominantly act on
neuronal membrane excitability.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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CNS effects of neuroactive substances can be tested non-
invasively with transcranial magnetic stimulation (TMS). TMS can
measure several functions of cortical excitability, such as axonal
membrane excitability of pyramidal tract neurons, and distinct
forms of intracortical synaptic excitability.1 In addition to some in
vitro or animal research, TMS can investigate brain functions at a
more comprehensive network level. This approach has been used
in the past to compare pharmaco-physiologic properties of
antiepileptic drugs of known action with newer substances, some
with incompletely understood pharmacological mechanisms or
multiple modes of action.2–5
Here we explored dose-depended effects of lacosamide (LCM)
and effects of carbamazepine (CBZ) on motor cortex excitability with
TMS in a randomized, double-blind, placebo-controlled crossover
trial in young healthy human subjects. It was found in vitro that LCM
selectively enhances slow inactivation of voltage-gated sodium* Corresponding author at: Department of Neurology, Christian-Albrechts-
University, Arnold-Heller-Str. 3, 24105 Kiel, Germany. Tel.: +49 597 8709;
fax: +49 597 8714.
E-mail address: n.lang@neurologie.uni-kiel.de (N. Lang).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.05.010channels, and, in contrast to CBZ, does not affect steady-state fast
inactivation.6 This mechanism of LCM to modulate sodium channels
leads to normalization of activation thresholds and reduced
pathophysiological hyper-responsiveness, without affecting physi-
ological activity.7 Therefore, it is thought that LCM, compared to CBZ,
will be better tolerated by patients while being as or even more
effective in controlling seizure activity.
On the basis of the results from nonhuman studies, we
hypothesized that the TMS proﬁles of LCM and CBZ could be
divergent. The idea behind this approach is not to use TMS to
distinguish between fast and slow sodium channel inactivation,
but to search for differential effects of the two drugs on the system
level, that studies on the cellular level were unable to detect. CBZ,
like other ‘classical’ sodium channel blockers such as phenytoin,
predominantly demonstrated increased TMS motor thresholds
indicating reduced neuronal membrane excitability, without
developing signiﬁcant changes of synaptic intracortical inhibition
and facilitation.4,8,9 Because of its novel mode of action it could
only be speculated which TMS parameters LCM might affect. More
than exclusively affecting neuronal membrane excitability, LCM
could possibly also affect inhibitory mechanisms such as short-
latency intracortical inhibition10 or stimulation-induced excitabil-
ity changes.11,12 This would be in line with other well-tolerated
modern antiepileptic drugs.2,4,5,13vier Ltd. All rights reserved.
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2.1. Subjects
Fifteen healthy young men (mean age 26  0.9 years; age range
19–32 years) gave their written informed consent to participate in the
study. Women were not included due to potential medication risks in
case of pregnancy. None of the subjects had any neurological or
psychiatric disorder, as evaluated by certiﬁed medical specialists with
experience in neurology (NL and HR). Further contraindications were:
cardiac disorders; known hypersensitivity against lacosamide,
carbamazepine, azoic dye or tricyclic antidepressants; acute inter-
mittent porphyria; bone marrow disorders; implants in the head;
drug or alcohol abuse; intake of any other medication and
participation in another clinical trial within the previous 8 weeks.
All subjects were consistent right-handers. Experimental procedures
were approved by the Ethics Committee of the University of Kiel
(Germany) and by the German Federal Institute for Drugs and Medical
Devices (Bundesinstitut fuer Arzneimittel und Medizinprodukte,
BfArM), and the study was performed according to the ethical
standards laid down in the Declaration of Helsinki. The study was
supported by a grant from UCB Pharma GmbH in Monheim
(Germany), monitored by the Center for clinical studies (Zentrum
fuer klinische Studien, ZKS) in Kiel and registered under www.Clin-
cialTrials.gov (NCT01382017).
2.2. Experimental design
The study was performed in a double-blind placebo-controlled
cross-over design. All ﬁfteen subjects participated in four drug
conditions, separated by at least 1 week. Uniform capsules,
containing 200 mg LCM, 100 mg LCM, 300 mg CBZ or placebo, were
orally administered 12 and 2 h before TMS measurements (Fig. 1).
This procedure has been used previously,2,14 since serum
concentrations and CNS effects can be expected to peak by the
time of TMS measurements.15,16 The order of drug conditions was
pseudorandomized and balanced between subjects, and subjects
and examiners were both blinded for them. TMS experiments were
all performed on the left primary motor cortex (M1) and at
identical times during morning hours with the subjects comfort-
ably seated in a reclining chair with head and arm rests. Surface
EMG from the right ﬁrst dorsal interosseus muscle (FDI) was
recorded through two Ag–AgCl surface electrodes placed over the
muscle belly and the tendon. Raw signals were ampliﬁed, band-
pass ﬁltered (3 Hz–2 kHz) and sampled at 5 kHz by a PC attached to
a micro 1401 AD converter (Cambridge Electronic Design, Cam-
bridge, UK) controlled by Signal Software (Cambridge Electronic
Design, version 4.08). Muscle relaxation was controlled by
auditory and visual feedback. Single- and paired pulse TMS was
performed by using a Magstim ﬁgure-eight-shaped 70-mm coil
connected to Magstim Bistim2 setup (Magstim Co., Dyfed, UK). The10 p.m. 
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Fig. 1. Experimental design. Fifteen healthy volunteers received 200 mg or 400 mg laco
double-blind cross-over design. Half of the dose was taken 12 h and half of it 2 h befor
(TMS).TMS coil was held over the left M1 with the handle pointing
posterior and lateral. The induced electrical ﬁeld of this coil
positioning is optimal for a transsynaptic activation of the
corticospinal system.17 The optimal site for eliciting motor-evoked
potentials (MEPs) in the resting right FDI was marked with a skin
marker to ensure that the coil was constantly held correct during
the experiment.
2.3. TMS measurements of cortical excitability
In each experimental session we measured the individual
resting motor threshold (RMT), active motor threshold (AMT), the
intensity to evoke MEP of 1-mV peak-to-peak amplitude
(SI1mV), short-interval intracortical inhibition/intracortical facili-
tation (SICI/ICF), recruitment curves (REC) and cortical silent
periods (CSP).
Stimulus intensities (in percentage of maximal stimulator
output) of TMS were determined at the beginning of each
experiment. SI1mV was determined with single-pulse TMS ﬁrst.
RMT was determined using the maximum likelihood threshold
hunting procedure18 when the ﬁrst dorsal interosseus muscle was
completely relaxed. For AMT we used the lowest TMS intensity at
which 50% of the stimuli elicited reliable MEP of approximately
200 mV in amplitude in the tonically contracting FDI.19 For SICI/ICF
two magnetic stimuli were given through the same stimulating
coil in random order at 0.25 Hz.10 The intensity of the conditioning
stimulus was set to 90% AMT and the test-stimulus intensity to
SI1mV. For SICI we used interstimulus intervals (ISI) of 2 ms and
4 ms, and for ICF ISIs of 9 ms and 12 ms. The control condition (test
pulse alone) was applied 40 times, and each of the conditioning-
test stimuli 20 times. The mean peak-to-peak amplitude of the
conditioned MEP at each ISI was expressed as a percentage of the
mean peak-to-peak size of the unconditioned test pulse. Mean SICI
was deﬁned as the mean percentage inhibition at ISIs of 2 and 4 ms,
whereas mean ICF was deﬁned as the mean facilitation at ISIs of 9
and 12 ms. Recruitment curves were measured with ten increasing
stimulus intensities (90%, 100%, 110%, 120%, 130%, 140%, 150%,
160%, 170%, and 180% of RMT), each with 8 pulses. A mean was
calculated for each intensity. At the end of each session, 10 pulses
with SI1mV and 10 pulses with 120% RMT were applied under
tonic contraction of the right ﬁrst dorsal interosseus muscle. Out of
these recordings CSPs were calculated in rectiﬁed and averaged
EMG traces with a prestimulus period of 100 ms. We measured the
CSP (in ms) from the TMS stimulus artefact to the point where the
EMG signal reached the amplitude of the mean prestimulus EMG
activity again for more than 5 ms.
2.4. Data analyses
The measures motor thresholds, SICI/ICF, recruitment and CSP
were analyzed with separate analyses of variance (ANOVAs) for10 a.m. 
TMS 
TMS 
TMS 
TMS 
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200 mg 
100 mg 
300 mg 
samide (LCM200, LCM400), 600 mg carbamazepine (CBZ600) or placebo (PLC) in a
e motor cortical excitability was examined with transcranial magnetic stimulation
Fig. 2. Compared to placebo (PLC), the intake of 600 mg carbamazepine (CBZ),
200 mg lacosamide (LCM200) or 400 mg lacosamide (LCM400) led to signiﬁcantly
higher mean motor thresholds (asterisks indicating p < 0.05). Analyses revealed
also a trend towards a dose dependent effect of lacosamide (hash, p = 0.067).
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subject as the dependent variable. Besides the factor ‘‘drug’’
(LCM200 vs. LCM400 vs. CBZ vs. PLC), the ANOVA model included
the factor ‘‘intensity’’ (AMT, RMT, SI1mV) when motor thresholds
were analyzed, or ‘‘ISI’’ (2, 4, 9, and 12 ms) when SICI/ICF was
analyzed, or ‘‘intensity’’ (90%, 100%, 110%, 120%, 130%, 140%, 150%,
160%, 170%, and 180% of RMT) for recruitment curves, or
‘‘intensity’’ (120% RMT and SI1mV) when CSPs were analyzed.
For motor thresholds and SICI/ICF means were calculated of
individual AMT, RMT and SI1mV values (mean motor threshold),
and of the individual 2 and 4 ms ISIs (mean SICI) or 9 and 12 ms ISIs
(mean ICF), respectively. When necessary the Greenhouse–Geisser
method was used to correct for nonsphericity. Dependent on a
signiﬁcant F value, post hoc analyses were performed with paired
samples two-tailed t-test, and a p value of <0.05 was considered
signiﬁcant for all statistical analyses. Data are expressed as
mean  SEM.
3. Results
Study medication was generally well tolerated. Subjects
reported altogether 14 transient adverse events after drug
administration in 60 experimental sessions, all being rated mild
to moderate and all resolving spontaneously within 6 h. Transient
adverse events (n per drug condition) were tiredness (PLC = 2, CBZ
600 = 3, LCM 400 = 3), nasopharyngitis (PLC = 1, LCM 400 = 1), oral
dysaesthesia (LCM 400 = 1), headache (LCM 400 = 1), apathy (LCM
400 = 1) and hypacusis (PLC = 1). None of these adverse events
interfered with the ability of the subjects to complete the study.
Effects of the four drug conditions on TMS motor thresholds are
summarized in Table 1. ANOVA on motor thresholds revealed
signiﬁcant main effects for ‘‘drug’’ (F(3,42) = 10.6, p < 0.001),
‘‘intensity’’ (F(2,28) = 78.9, p < 0.001), and for the interaction ‘‘drug’’
by ‘‘intensity’’ (F(6,84) = 2.9, p = 0.012). Post hoc comparisons
demonstrated that mean motor thresholds signiﬁcantly differed
for the following pairs: PLC vs. CBZ (t = 5.5; df = 14; p < 0.001),
PLC vs. LCM200 (t = 2.8; df = 14; p = 0.015) and PLC vs. LCM400
(t = 5.5; df = 14; p < 0.001). The comparison of LCM200 vs.
LCM400 revealed a trend for a dose-dependent effect of lacosamide
on motor thresholds (t = 2.0; df = 14; p = 0.067). Effects of
carbamazepine on motor thresholds did not signiﬁcantly differ
from those of lacosamide, regardless of the dosage (p values > 0.1)
(Fig. 2). Signiﬁcant effects were also found in separate post hoc
comparisons on the three motor threshold parameters (RMT: PLC
vs. CBZ (t = 5.5; df = 14; p < 0.001), PLC vs. LCM400 (t = 5.3;
df = 14; p < 0.001); AMT: PLC vs. CBZ (t = 4.0; df = 14; p = 0.001),
PLC vs. LCM200 (t = 2.4; df = 14; p = 0.034), PLC vs. LCM400
(t = 4.1; df = 14; p = 0.001); SI1mV: PLC vs. CBZ (t = 4.8; df = 14;
p < 0.001), PLC vs. LCM200 (t = 2.4; df = 14; p = 0.029), PLC vs.
LCM400 (t = 3.5; df = 14; p = 0.03).
All other analyses did not reach signiﬁcance, indicating no
differential drug effects for SICI/ICF (‘‘drug’’: F(3,42) = 0.2, p = 0.860,
‘‘ISI’’: F(1,14) = 50.7, p < 0.001, interaction ‘‘drug’’ by ‘‘ISI’’:
F(3,42) = 3.1, p = 0.165), recruitment curves (‘‘drug’’: F(3,42) = 1.2,Table 1
Mean values (in % of maximal stimulator output) for active motor thresholds (AMT),
resting motor thresholds (RMT), the intensities necessary to evoke MEP of 1-mV
peak-to-peak amplitude (SI1mV) and mean motor thresholds (1MT), given for all
four drug conditions (PLC, placebo; CBZ, carbamazepine 600 mg; LCM200,
lacosamide 200 mg; LCM400, lacosamide 400 mg).
AMT RMT SI1mV 1MT
PLC 31  1% 43  2% 51  2% 43  2%
CBZ 34  1% 47  2% 58  3% 48  2%
LCM200 33  1% 45  2% 56  4% 46  3%
LCM400 34  1% 48  2% 58  4% 48  3%p = 0.315, ‘‘intensity’’: F(9,126) = 94.6, p < 0.001, interaction ‘‘drug’’
by ‘‘intensity’’: F(27,378) = 1.9, p = 0.139), and cortical silent periods
(‘‘drug’’: F(3,42) = 0.7, p = 0.527, ‘‘intensity’’: F(1,14) = 0.2, p = 0.675,
interaction ‘‘drug’’ by ‘‘intensity’’: F(3,42) = 1.7, p = 0.2).
4. Discussion
Here we used TMS to investigate acute effects of lacosamide
and carbamazepine on human motor cortex excitability. The
results demonstrate that both, lacosamide and carbamazepine,
signiﬁcantly increase TMS motor thresholds compared to placebo.
Analyses revealed no signiﬁcant difference between threshold
changes after lacosamide and carbamazepine, but showed a trend
for a dose-dependent effect of lacosamide with higher thresholds
after 400 mg lacosamide compared to 200 mg. Other TMS
parameters of cortical excitability, such as intracortical inhibition
and facilitation or cortical silent periods, were not altered after
acute intake of both antiepileptic drugs.
Motor thresholds are global measures of corticospinal excit-
ability, reﬂecting neuronal membrane excitability.20,21 In patch-
clamp studies phenytoin and carbamazepine block the inactive
form of closed sodium channels,22,23 and in the human corticosp-
inal tract both substances increase motor thresholds, without
pronounced effects on intracortical inhibition or facilitation.4,9 In
contrast to carbamazepine, lacosamide selectively enhances slow
inactivation of voltage-gated sodium channels without affecting
fast inactivation.7 However, in the present study a differential
effect compared to carbamazepine could not be demonstrated
with means of TMS. Both lacosamide and carbamazepine devel-
oped clear effects on neuronal membrane excitability, without
affecting synaptic excitability parameters.
Our results basically conﬁrm previous studies on CBZ,4,24 apart
from a missing effect on CSP in the present study that may be due
to different methodological approaches. Regarding TMS physiolo-
gy they are in good line with results on other antiepileptic drugs
that interact with voltage-gated sodium channels, not only
phenytoin and carbamazepine, but also ‘modern’ antiepileptic
drugs like oxcarbazepine25 and lamotrigine.26 Since the mecha-
nism of action of oxcarbazepine is considered more or less
‘classical’ sodium channel blockade, it may not be surprising that
its TMS proﬁle resembles that of phenytoin and carbamazepine.
Unlike lamotrigine, that shows a similar TMS proﬁle, but differs
substantially in its clinical use. Despite its sodium channel blocking
mechanism, lamotrigine often appears to be a good treatment
Table 2
Comparison of acute antiepileptic drug effects (ordered by their main target structure) on different cortical excitability parameters tested with transcranial magnetic
stimulation (TMS). (~) Increase, (!) decrease, (*) unchanged; CBZ, carbamazepine; OXC, oxcarbazepine; PHT, phenytoin; LTG, lamotrigine; LCM, lacosamide; GBP,
gabapentin; PGB, pregabalin; DZP, diazepam; VGB, vigabatrine; TGB, tiagabine; VPA, valproate; LEV, levetiracetam; TPM, topiramate.
MT SICI ICF CSP Reference
Sodium channel CBZ ~ * * * Ziemann et al.4
OXC ~ * * * Kimiskidis et al.25
PHT ~ * * * Chen et al.9
LTG ~ * * * Boroojerdi et al.26
LCM ~ * * * Present study
Calcium channel GBP * ~ ! ~ Rizzo et al.40 and Ziemann et al.4
PGB * ! * ~ Lang et al.11
GABA-A receptor DZP * ~ ! ! Inghilleri et al.13
VGB * * !/* */~ Pierantozzi et al.44
TGB * ! ~ ~ Werhahn et al.39
Other VPA * * * * Ziemann et al.37 and Zunhammer et al.45
LEV ~ * * * Reis et al.33 and Sohn et al.3
TPM * ~ ! * Reis et al.5
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although many of these patients do not tolerate carbamazepine or
phenytoin29,30; and even levetiracetam, which binds to the
synaptic vesicle protein SV2A31 and does seem to not interact
directly with sodium channels,32 leads to increased TMS motor
thresholds.33 Therefore, it can be concluded that under the TMS
parameter ‘motor threshold’ different physiological and pharma-
cological mechanisms are subsumed, and drug-induced changes of
this parameter do not predict whether an agent could be
appropriate or inappropriate for certain epilepsy syndromes. This
is in line with ﬁrst reports indicating that lacosamide may also be
tolerated in generalized epilepsies,34,35 despite having a TMS
proﬁle similar to carbamazepine.
Our results do not indicate that lacosamide or carbamazepine
alter intracortical synaptic excitability, such as SICI/ICF or CSPs.
While SICI/ICF reﬂects excitability of inhibitory and excitatory
cortical interneurons, primarily of the glutamatergic and GABA-A
circuits,4,9,36,37 CSPs involve GABA-B-receptor activity.38,39 None of
these mechanisms seems to be affected by lacosamide and
carbamazepine. Other antiepileptic drugs can alter intracortical
synaptic excitability (SICI/ICF and CSPs), e.g. gabapentin and
pregabalin,2,4,40 which are regarded as modulators of calcium
channel activity, or topiramate,5 which has many known mecha-
nisms of action, such as enhanced GABA-mediated inhibition,
inhibition of voltage-gated sodium channels, enhanced potassium
channel conduction, inhibition of calcium channels, decrease of
glutamate-mediated excitatory neurotransmission and carbonic
anhydrase inhibition. For most antiepileptic drugs multiple
mechanisms of action could be described by cellular physiology,
mostly by using patch-clamp technique. However, it can be
expected that further mechanisms exist and are still unknown.
Interestingly, the proﬁles described with cellular physiology often
do not match those described with TMS, and substances that seem
similar in one way, appear different in the other (Table 2). For the
clinician this divergence supports the experience, that when
choosing optimal treatment for epilepsy patients mechanisms of
actions are rather secondary.
TMS studies on pharmacodynamics of antiepileptic drugs are
not free of limitations. These may lie in the result’s transferability
from healthy subjects to patients, since patients can show different
responses to TMS or drugs compared to healthy controls,41,42 or in
the approach of a short-term drug administration, which can
produce effects different from responses of the human brain to a
drug administered over the long term.8,43 On the other hand, TMS
allows exploring noninvasively the mode of action of a drug in the
intact human and comparing the pattern of excitability changeswith those induced by other agents. In addition to cellular
physiology, TMS can describe qualitative and quantitative changes
at the system level of the human cerebral cortex. Our knowledge
about pharmacokinetics of new antiepileptic drugs or substances
with possible use as antiepileptic drugs in the future, such as
perampanel or briveracetam, will beneﬁt from this comparative
research.
In conclusion the present study demonstrates that lacosamide
mainly acts on neuronal membrane excitability. TMS, which can be
useful to examine drug effects on the system level of the human
motor cortex, did not show lacosamide-induced changes of
intracortical synaptic excitability and no signiﬁcant difference to
effects induced by carbamazepine. This does not contradict results
obtained with methods of cellular physiology.
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